Cell therapy companies face many hurdles. I wrote recently about four cell therapy biotechs that have been really struggling. Blogging here at The Niche for more than a dozen years, I’ve seen many companies even go under. That’s bad news for the field, for patients, and for investors. Today I wanted to highlight some cell therapy […]
3 cell therapy companies doing well: Vertex, Vericel, & Regeneron Read More »
It’s funny how sometimes there are many new articles about one general topic like this week with heritable (and somatic) human CRISPR gene editing and related tech. There are clear reasons for optimism in the somatic arena given advancing trials. Germline editing remains highly questionable in my view even just technically. Then there are loads
Weekly reads: human CRISPR, MRT risks, private IRBs, skincare Read More »
How promising is the idea of stem cells for MS? I have been working slowly as time permits on a piece more specifically about hematopoietic stem cell transplantation (HSCT) for MS. Two new pieces caught my eye on this topic so I’ll start with those. Stem cells for MS NurOwn Found Safe, Shows Promise in
Weekly reads: stem cells for MS, blood origins, iPSCs Read More »
Today’s post includes a list of firms/products that have self-reported that they have received FDA regenerative medicine advanced therapy designation or RMAT. Sometimes people call these “r mat” with a space. As of December 12, 2023 there are 85 RMATs in the public domain. I also include FDA data on RMAT submissions via an FDA RMAT resource
Updated FDA granted RMAT List (85) Read More »